Romiplostim CAS 267639-76-9 is a synthetic protein used to treat thrombocytopenia, a condition characterized by low platelet counts in the blood. It is marketed under the brand name Nplate and was first approved by the FDA in 2008. Romiplostim belongs to a class of drugs called thrombopoietin receptor agonists that mimic the action of thrombopoietin, a hormone that regulates platelet production.
Chemical Name:
The chemical name of romiplostim is (pegylated) recombinant human thrombopoietin mimetic peptide.
Molecular Formula:
The molecular formula of romiplostim is C845H1343N223O263S13.
Formula Weight:
The formula weight of romiplostim is 19178.5 g/mol.
CAS No:
The CAS number of romiplostim is 267639-76-9.
Top Ten Keywords and Synonyms:
Synonyms:
Health Benefits:
Romiplostim is primarily used to treat thrombocytopenia in patients with chronic immune thrombocytopenia (ITP). ITP is a disorder where the immune system mistakenly attacks and destroys platelets, resulting in low platelet counts. Romiplostim stimulates the production of megakaryocytes in the bone marrow, which are responsible for producing platelets. By increasing the number of megakaryocytes, romiplostim increases the production of platelets, thereby improving clotting function and reducing the risk of bleeding in patients with ITP.
Potential Effects:
Romiplostim has been shown to be effective in increasing platelet counts in patients with ITP. In clinical trials, romiplostim was found to be more effective than placebo in achieving a sustained platelet response. Patients treated with romiplostim also had a decreased incidence of bleeding events compared to placebo.
Product Mechanism:
Romiplostim works by binding to and activating the thrombopoietin receptor on the surface of bone marrow cells, stimulating the production of megakaryocytes, which produce platelets. By mimicking the action of thrombopoietin, romiplostim increases the production of platelets, which helps to reduce the risk of bleeding in patients with ITP.
Safety:
Like all medications, romiplostim can cause side effects. Patients who have received romiplostim may experience injection site reactions, headache, fatigue, joint pain, or nausea. There have also been reports of serious adverse events associated with romiplostim use, including increased risk of blood clots, progression to leukemia or myelodysplastic syndrome, and autoimmune disorders. Patients should discuss the potential risks and benefits of romiplostim with their healthcare provider before starting treatment.
Side Effects:
Common side effects of romiplostim include headache, fatigue, joint pain, and injection site reactions. Serious adverse events associated with romiplostim use include increased risk of blood clots, progression to leukemia or myelodysplastic syndrome, and autoimmune disorders.
Dosing Information:
The dosing of romiplostim varies depending on the patient's platelet count and response to treatment. The recommended starting dose is 1 mcg/kg once weekly subcutaneously. Doses may be adjusted based on the patient's platelet count and response to treatment, up to a maximum of 10 mcg/kg once weekly.
Conclusion:
Romiplostim is a thrombopoietin receptor agonist used to treat thrombocytopenia in patients with chronic immune thrombocytopenia. By increasing the production of platelets, romiplostim helps to improve clotting function and reduce the risk of bleeding in patients with ITP. However, like all medications, romiplostim can have side effects and may increase the risk of serious adverse events. Patients should discuss the potential risks and benefits of romiplostim with their healthcare provider before starting treatment.
